Literature DB >> 30837674

The human antibody response to influenza A virus infection and vaccination.

Florian Krammer1.   

Abstract

The adaptive immune response to influenza virus infection is multifaceted and complex, involving antibody and cellular responses at both systemic and mucosal levels. Immune responses to natural infection with influenza virus in humans are relatively broad and long-lived, but influenza viruses can escape from these responses over time owing to their high mutation rates and antigenic flexibility. Vaccines are the best available countermeasure against infection, but vaccine effectiveness is low compared with other viral vaccines, and the induced immune response is narrow and short-lived. Furthermore, inactivated influenza virus vaccines focus on the induction of systemic IgG responses but do not effectively induce mucosal IgA responses. Here, I review the differences between natural infection and vaccination in terms of the antibody responses they induce and how these responses protect against future infection. A better understanding of how natural infection induces broad and long-lived immune responses will be key to developing next-generation influenza virus vaccines.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30837674     DOI: 10.1038/s41577-019-0143-6

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  183 in total

Review 1.  Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly.

Authors:  Roberto Gasparini; Daniela Amicizia; Piero Luigi Lai; Donatella Panatto
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

Review 2.  Emerging influenza viruses and the prospect of a universal influenza virus vaccine.

Authors:  Florian Krammer
Journal:  Biotechnol J       Date:  2015-03-02       Impact factor: 4.677

3.  The annual production cycle for influenza vaccine.

Authors:  Catherine Gerdil
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

Review 4.  The emergence of pandemic influenza viruses.

Authors:  Yi Guan; Dhanasekaran Vijaykrishna; Justin Bahl; Huachen Zhu; Jia Wang; Gavin J D Smith
Journal:  Protein Cell       Date:  2010-02-07       Impact factor: 14.870

Review 5.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

6.  Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic.

Authors:  Gavin J D Smith; Dhanasekaran Vijaykrishna; Justin Bahl; Samantha J Lycett; Michael Worobey; Oliver G Pybus; Siu Kit Ma; Chung Lam Cheung; Jayna Raghwani; Samir Bhatt; J S Malik Peiris; Yi Guan; Andrew Rambaut
Journal:  Nature       Date:  2009-06-25       Impact factor: 49.962

7.  Avian influenza H7N9 viruses: a rare second warning.

Authors:  Kanta Subbarao
Journal:  Cell Res       Date:  2017-12-01       Impact factor: 25.617

8.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins.

Authors:  Nicholas S Heaton; David Sachs; Chi-Jene Chen; Rong Hai; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

Review 9.  Influenza.

Authors:  Florian Krammer; Gavin J D Smith; Ron A M Fouchier; Malik Peiris; Katherine Kedzierska; Peter C Doherty; Peter Palese; Megan L Shaw; John Treanor; Robert G Webster; Adolfo García-Sastre
Journal:  Nat Rev Dis Primers       Date:  2018-06-28       Impact factor: 52.329

10.  The influenza virus hemagglutinin head evolves faster than the stalk domain.

Authors:  Ericka Kirkpatrick; Xueting Qiu; Patrick C Wilson; Justin Bahl; Florian Krammer
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more
  168 in total

1.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

Review 2.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

3.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

Review 4.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

5.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

6.  Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.

Authors:  Meito Shibuya; Taiki Aoshi; Etsushi Kuroda; Yasuo Yoshioka
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

7.  A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.

Authors:  Xingui Tian; Shelby Landreth; Yao Lu; Kannupriya Pandey; Yan Zhou
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

8.  Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.

Authors:  Peiyang Ding; Qianyue Jin; Xinxin Chen; Suzhen Yang; Junqing Guo; Guangxu Xing; Ruiguang Deng; Aiping Wang; Gaiping Zhang
Journal:  Int J Nanomedicine       Date:  2019-09-16

9.  Broadly protective human antibodies that target the active site of influenza virus neuraminidase.

Authors:  Daniel Stadlbauer; Xueyong Zhu; Meagan McMahon; Jackson S Turner; Teddy J Wohlbold; Aaron J Schmitz; Shirin Strohmeier; Wenli Yu; Raffael Nachbagauer; Philip A Mudd; Ian A Wilson; Ali H Ellebedy; Florian Krammer
Journal:  Science       Date:  2019-10-25       Impact factor: 47.728

10.  Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.

Authors:  Anders Madsen; Ya-Nan Dai; Meagan McMahon; Aaron J Schmitz; Jackson S Turner; Jessica Tan; Tingting Lei; Wafaa B Alsoussi; Shirin Strohmeier; Mostafa Amor; Bassem M Mohammed; Philip A Mudd; Viviana Simon; Rebecca J Cox; Daved H Fremont; Florian Krammer; Ali H Ellebedy
Journal:  Immunity       Date:  2020-09-24       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.